Novartis Ag Stock Price Prediction
| NVSEF Stock | USD 104.00 5.75 5.85% |
Oversold Vs Overbought
41
Oversold | Overbought |
Using Novartis hype-based prediction, you can estimate the value of Novartis AG from the perspective of Novartis response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Novartis to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Novartis because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Novartis after-hype prediction price | USD 104.0 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Novartis |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Novartis' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Novartis After-Hype Price Prediction Density Analysis
As far as predicting the price of Novartis at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Novartis or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Novartis, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Novartis Estimiated After-Hype Price Volatility
In the context of predicting Novartis' pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Novartis' historical news coverage. Novartis' after-hype downside and upside margins for the prediction period are 101.71 and 106.29, respectively. We have considered Novartis' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Novartis is very steady at this time. Analysis and calculation of next after-hype price of Novartis AG is based on 3 months time horizon.
Novartis Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Novartis is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Novartis backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Novartis, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.14 | 2.30 | 0.00 | 0.02 | 0 Events / Month | 4 Events / Month | Uncertain |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
104.00 | 104.00 | 0.00 |
|
Novartis Hype Timeline
Novartis AG is now traded for 104.00. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.02. Novartis is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is now at -0.14%. %. The volatility of related hype on Novartis is about 1306.82%, with the expected price after the next announcement by competition of 104.02. About 34.0% of the company shares are owned by institutional investors. The book value of Novartis was now reported as 28.0. The company last dividend was issued on the 9th of March 2023. Novartis AG had 40:1 split on the 7th of May 2001. Assuming the 90 days horizon the next forecasted press release will be uncertain. Check out Novartis Basic Forecasting Models to cross-verify your projections.Novartis Related Hype Analysis
Having access to credible news sources related to Novartis' direct competition is more important than ever and may enhance your ability to predict Novartis' future price movements. Getting to know how Novartis' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Novartis may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| SNY | Sanofi ADR | 0.09 | 10 per month | 0.00 | (0.27) | 1.74 | (1.85) | 7.81 | |
| BMY | Bristol Myers Squibb | 1.73 | 7 per month | 1.18 | 0.12 | 2.23 | (2.07) | 14.39 | |
| AZN | AstraZeneca PLC ADR | (0.58) | 8 per month | 0.00 | (0.35) | 1.28 | (3.18) | 8.50 | |
| GILD | Gilead Sciences | 0.20 | 7 per month | 1.00 | 0.11 | 2.17 | (1.82) | 10.80 | |
| NVS | Novartis AG ADR | (0.56) | 11 per month | 0.00 | (0.32) | 1.12 | (1.98) | 6.05 |
Novartis Additional Predictive Modules
Most predictive techniques to examine Novartis price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Novartis using various technical indicators. When you analyze Novartis charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Novartis Predictive Indicators
The successful prediction of Novartis stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Novartis AG, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Novartis based on analysis of Novartis hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Novartis's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Novartis's related companies.
Story Coverage note for Novartis
The number of cover stories for Novartis depends on current market conditions and Novartis' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Novartis is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Novartis' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Novartis Short Properties
Novartis' future price predictability will typically decrease when Novartis' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Novartis AG often depends not only on the future outlook of the potential Novartis' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Novartis' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.1 B |
Complementary Tools for Novartis Pink Sheet analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |